Skip to main content

Advertisement

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

Article metrics

The original article was published in BMC Urology 2018 18:77

Correction to Schultz et al. BMC Urology (2018) 18:77 DOI: 10.1186/s12894-018-0387-7

It has been highlighted that in the original article [1] there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.

Incorrect:

The NNT for rPFS at 2 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

Correct:

The NNT for rPFS at 1 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

Reference

  1. 1.

    Schultz NM, et al. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol. 2018;18:77.

Download references

Author information

Correspondence to Neil M Schultz.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schultz, N.M., Shore, N.D., Chowdhury, S. et al. Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol 18, 84 (2018) doi:10.1186/s12894-018-0397-5

Download citation